- Report
- July 2026
- 160 Pages
Global
From €3727EUR$4,150USD£3,184GBP
- Report
- January 2026
- 198 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2026
- 183 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2026
- 197 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- January 2026
- 188 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- August 2026
- 272 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- August 2026
- 181 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- August 2026
- 148 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- January 2026
- 182 Pages
Global
From €4042EUR$4,500USD£3,453GBP
- Report
- November 2025
- 180 Pages
Global
From €4042EUR$4,500USD£3,453GBP
- Report
- April 2026
- 30 Pages
Global
From €2470EUR$2,750USD£2,110GBP
- Report
- April 2026
- 30 Pages
Global
From €2470EUR$2,750USD£2,110GBP

Hydroxycarbamide is a drug used to treat chronic myeloid leukemia (CML). It is a type of chemotherapy drug that works by inhibiting the growth of cancer cells. It is also used to treat polycythemia vera, a rare blood disorder. Hydroxycarbamide is usually taken orally in tablet form, and is usually taken once or twice a day. It is also available in an injectable form. Common side effects of hydroxycarbamide include nausea, vomiting, diarrhea, and hair loss.
Hydroxycarbamide is a relatively new drug, and is still in the process of being approved by regulatory bodies in different countries. It is currently approved in the United States, Canada, and the European Union. It is also approved in some other countries, such as Australia, New Zealand, and South Africa.
Hydroxycarbamide is marketed by several pharmaceutical companies, including Novartis, Bristol-Myers Squibb, and Pfizer. Other companies that market hydroxycarbamide include Cipla, Teva Pharmaceuticals, and Mylan. Show Less Read more